

Contact: Doug Guarino
Jon Russell

Director of Corporate Relations
Vice President of Finance

781-647-3900

**ALERE INC. ANNOUNCES
FIRST QUARTER 2013 RESULTS**

WALTHAM, MA...May 9, 2013...Alere Inc. (NYSE: **ALR**), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health information solutions, today announced its financial results for the quarter ended March 31, 2013.

Ron Zwanziger, Chairman, Chief Executive Officer and President of Alere said, "I'm pleased to report another quarter of progress across the organization. With our company formation substantially complete, and the areas of pressure with Triage and Health Information Solutions showing signs of stability, we were able to take key steps to drive improved operating expense leverage in the first quarter."

Zwanziger added, "Broad changes to healthcare systems in most major markets are driving increasing opportunities for Alere's integrated offering. As we continue to combine new diagnostic platforms and services into an integrated, technology-based solution focused on the most expensive chronic conditions, we expect to benefit from these persistent and predictable global trends. Our unique position to capitalize on the evolution of global healthcare, combined with a sustained focus on organic revenue growth, operating expense leverage and debt reduction over the next several years, should continue to engender increasing shareholder confidence in our company and our prospects for future success."

Financial results for the first quarter of 2013:

- Net revenue of \$739.2 million for the first quarter of 2013, compared to \$671.1 million for the first quarter of 2012. Non-GAAP adjusted net revenue, which includes approximately \$0.6 million in estimated revenue related to acquired software license contracts not recognized for GAAP purposes for the first quarter of 2013 due to business combination accounting rules, was \$739.9 million for the first quarter of 2013, compared to \$672.4 million for the first quarter of 2012, which included \$1.3 million in estimated revenue related to acquired software license contracts not recognized for GAAP purposes.
- Net income of \$7.2 million attributable to common stockholders of Alere Inc., and respective net income per diluted common share of \$0.09, for the first quarter of 2013, compared to net loss of \$4.1

million attributable to common stockholders of Alere Inc., and respective net loss per diluted common share of \$0.05, for the first quarter of 2012.

- Non-GAAP adjusted net income per diluted common share of \$0.53 for the first quarter of 2013, compared to non-GAAP adjusted net income per diluted common share of \$0.77 for the first quarter of 2012.
- Net product and services revenue from our Professional Diagnostics segment was \$578.6 million in the first quarter of 2013, compared to net product and services revenue of \$515.4 million in the first quarter of 2012. Non-GAAP adjusted net product and services revenue from our Professional Diagnostics segment, which includes approximately \$0.6 million in estimated revenue related to acquired software license contracts not recognized for GAAP purposes for the first quarter of 2013 due to business combination accounting rules, was \$579.3 million in the first quarter of 2013, compared to non-GAAP adjusted net product and services revenue of \$516.7 million in the first quarter of 2012, which included \$1.3 million in estimated revenue related to acquired software license contracts not recognized for GAAP purposes. Recent professional diagnostics acquisitions contributed \$62.0 million of incremental net revenue compared to the first quarter of 2012.
- North American influenza sales increased to \$34.3 million for the first quarter of 2013, from \$6.6 million for the first quarter of 2012.
- Excluding the impact of the change in North American influenza revenues and the impact on revenues from the reduction in our U.S. meter-based Triage product sales, currency adjusted organic growth in our Professional Diagnostics segment was 1.1%.
- Net product and services revenue from our Health Information Solutions segment was \$134.2 million in the first quarter of 2013, compared to \$130.8 million in the first quarter of 2012 and \$131.0 million in the fourth quarter of 2012. The increase in revenue from the first quarter of 2012 was related primarily to increased revenues from our home coagulation monitoring programs.
- Other income for the first quarter of 2012 includes \$13.5 million of a final royalty termination payment received from Quidel during the quarter, offset by \$2.3 million of other charges. Together, and net of tax, these other income items added approximately \$0.12 to our non-GAAP adjusted net income per diluted common share for the quarter.

The Company's GAAP results for the first quarter of 2013 exclude \$0.6 million of revenue associated with acquired software license contracts that are not recognized due to business combination accounting rules and include amortization of \$76.0 million, \$3.9 million of restructuring charges, \$4.1 million of stock-based compensation expense, \$0.9 million of acquisition-related costs recorded in accordance with ASC 805, *Business Combinations*, \$11.0 million of expense recorded for fair value adjustments to

acquisition-related contingent consideration, \$1.0 million of interest expense recorded in connection with fees paid for certain debt modifications, \$0.7 million in compensation charges associated with acquisition-related contingent consideration obligations, a \$0.5 million charge associated with the write-up to fair market value of inventory acquired in connection with the acquisition of Epocal Inc. and \$0.2 million of expense associated with the extinguishment of debt. The Company's GAAP results for the first quarter of 2012 exclude \$1.3 million of revenue associated with acquired software license contracts that are not recognized due to business combination accounting rules and include amortization of \$78.1 million, \$5.6 million of restructuring charges, \$3.9 million of stock-based compensation expense, \$1.5 million of acquisition-related costs recorded in accordance with ASC 805, *Business Combinations*, \$5.0 million of income recorded for fair value adjustments to acquisition-related contingent consideration obligations, \$1.3 million of interest expense associated with fees paid for modification of certain debt agreements and a \$4.7 million charge associated with the write-up to fair market value of inventory acquired in connection with the acquisition of Axis-Shield plc. These amounts, net of tax, have been excluded from the non-GAAP adjusted net income per diluted common share attributable to Alere Inc. for the respective quarters.

Detailed reconciliations of the Company's non-GAAP adjusted operating income and non-GAAP adjusted net income available to common shareholders to operating income and net loss available to common shareholders under GAAP, as well as a discussion regarding these non-GAAP financial measures, is included in the schedules to this press release.

The Company will host a conference call beginning at 8:30 a.m. (Eastern Time) today, May 9, 2013, to discuss these results, as well as other corporate matters. During the conference call, the Company may answer questions concerning business and financial developments and trends and other business and financial matters. The Company's responses to these questions, as well as other matters discussed during the conference call, may contain or constitute information that has not been previously disclosed.

The conference call may be accessed by dialing (877) 270-2148 (domestic) or (412) 902-6510 (international) and asking for Alere Inc. A webcast of the call can also be accessed via the Alere website at www.alere.com/investors, or directly through the following link: <http://www.videonewswire.com/event>.

A replay of the call will be available approximately one hour after the conclusion of the call and will remain available for a period of seven days following the call. The replay may be accessed by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and entering replay code 10028513. The

replay will also be available via online webcast at <http://www.videonewswire.com/event> or via the Alere website at www.alere.com/investors for a period of 60 days following the call.

Additionally, reconciliations to non-GAAP financial measures not included in this press release that may be discussed during the call will also be available at the Alere website (<http://www.alere.com/investors>) under the Earnings Calls and Releases section shortly before the conference call begins and will continue to be available on this website.

For more information about Alere, please visit our web site at <http://www.alere.com>.

By developing new capabilities in near-patient diagnosis, monitoring and health information solutions, Alere enables individuals to take charge of improving their health and quality of life at home. Alere's global leading products and services, as well as its new product development efforts, focus on cardiology, infectious disease, toxicology and diabetes. Alere is headquartered in Waltham, Massachusetts.

Source: Alere Inc.